Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies
Theranostics · 2024 · 14 (9) · 3404-3422
DOI: 10.7150/thno.93973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, 2024. Verfasst von Hamid Abdollahi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 69-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Radiopharmaceutical therapy (RPT) is a rapidly developing field of nuclear medicine, with several RPTs already well established in the treatment of several different types of cancers. However, the current approaches to RPTs often follow a somewhat inflexible "one size fits all" paradigm, where patients are administered the same amount of radioactivity per cycle regardless of their individual characteristics and features. This approach fails to consider inter-patient variations in radiopharmacokinetics, radiation biology, and immunological factors, which can significantly impact treatment outcomes. To address this limitation, we propose the development of theranostic digital twins (TDTs) to personalize RPTs based on actual patient data. Our proposed roadmap outlines the steps needed to create and refine TDTs that can optimize radiation dose to tumors while minimizing toxicity to organs at risk. The TDT models incorporate physiologically-based radiopharmacokinetic (PBRPK) models, which are additionally linked to a radiobiological optimizer and an immunological modulator, taking into account factors that influence RPT response. By using TDT models, we envisage the ability to perform virtual clinical trials, selecting therapies towards improved treatment outcomes while minimizing risks associated with secondary effects. This framework could empower practitioners to ultimately develop tailored RPT solutions for subgroups and individual patients, thus improving the precision, accuracy, and efficacy of treatments while minimizing risks to patients. By incorporating TDT models into RPTs, we can pave the way for a new era of precision medicine in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, University of British Columbia, Vancouver, Canada.
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, Canada.
- Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
- Department of Cardiology, University Hospital Bern, Switzerland.
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
- Department of Biomedical Engineering, University of British Columbia, Vancouver, Canada.
Zitieren
APA
Abdollahi, H., Yousefirizi, F., Shiri, I., Brosch-Lenz, J., Mollaheydar, E., Fele-Paranj, A., Shi, K., Zaidi, H., Alberts, I., Soltani, M., Uribe, C., Saboury, B., & Rahmim, A. (2024). Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies. Theranostics, 14(9), 3404-3422. https://doi.org/10.7150/thno.93973
Vancouver
Abdollahi H, Yousefirizi F, Shiri I, Brosch-Lenz J, Mollaheydar E, Fele-Paranj A, et al. Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies. Theranostics. 2024;14(9):3404-3422. doi:10.7150/thno.93973
BibTeX
@article{Abdollahi2024,
author = {Abdollahi, Hamid and Yousefirizi, Fereshteh and Shiri, Isaac and Brosch-Lenz, Julia and Mollaheydar, Elahe and Fele-Paranj, Ali and Shi, Kuangyu and Zaidi, Habib and Alberts, Ian and Soltani, Madjid and Uribe, Carlos and Saboury, Babak and Rahmim, Arman},
title = {Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies},
journal = {Theranostics},
year = {2024},
volume = {14},
number = {9},
pages = {3404--3422},
doi = {10.7150/thno.93973}
}
EUVIMED